Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Pulmonology
•
Lung Transplant
•
IPF
Do you assess telomere length in all patients with IPF prior to lung transplant?
Related Questions
Is there an age at which you consider not starting antifibrotic therapy in a patient with IPF?
What agents do you utilize for mucociliary clearance during the index hospitalization of patients post lung transplant?
Do you consider administration of nintedanib or pirfenidone via enteral tube in patients unable to take PO due to recurrent aspiration?
Do you consider surgical thrombectomy in patients with a large, obstructive pulmonary venous thrombosis after lung transplant?
How do you manage immunosuppressive medications in patients who develop a pneumonia?
Do you ever consider close clinical monitoring over antifibrotic therapy in patients ascribed an MDD diagnosis of IPF who have normal lung function and are asymptomatic?
What are your top takeaways from ISHLT 2024?
Do you treat A0B1 rejection noted on surveillance bronchoscopy in a patient less than one year post lung transplant?
What are the next steps in the management of a patient admitted with an IPF exacerbation resistant to steroid therapy?
When do you entertain a diagnosis of HLA-negative antibody mediated rejection in lung transplant recipients?
